News Center
Livzon Pharmaceutical and Neosyn Pharmaceuticals have reached an exclusive licensing agreement for the highly selective KCNQ2/3 activator NS-041 in the Greater China region.
Release time:
2024-07-18
Recently, the wholly-owned subsidiary of Livzon Pharmaceutical Group Inc., Livzon Group Livzon Pharmaceutical Factory (hereinafter referred to as "Livzon Pharmaceutical"), reached an exclusive licensing agreement for the Greater China region with NeurAxon Pharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "NeurAxon Pharmaceuticals")—an international biotechnology company focused on developing innovative therapies for neurological and psychiatric diseases—regarding NeurAxon's global intellectual property for the small molecule candidate drug NS-041. The two parties will closely collaborate on the development and accelerate the market launch of NS-041.
According to the terms of the agreement, Livzon Pharmaceutical will exclusively obtain all rights and interests of NS-041 in the Greater China region. Livzon Pharmaceutical will work closely with NeurAxon Pharmaceuticals to promote the subsequent development of NS-041 in the Greater China region, while NeurAxon Pharmaceuticals will continue to lead the development and commercialization of NS-041 in other global regions.
NS-041 is a highly selective KCNQ2/3 activator, aimed at treating neurological and psychiatric diseases such as epilepsy and depression.NS-041 has demonstrated good and differentiated preclinical efficacy and safety data, with the potential to become best-in-class. A randomized, double-blind, placebo-controlled Phase I clinical study has already been initiated in China.
Potassium ion channels KCNQ2/3 are considered one of the important targets for the development of next-generation antiepileptic drugs, and their novel mechanism of action is expected to address the shortcomings of current treatment methods. In addition, the potential indications for this target can be expanded to various mood disorders, aiming to address the clinical unmet needs such as slow onset and insufficient efficacy of existing drugs. Currently, global candidate drugs targeting the same site are in clinical research stages and have obtained positive data in epilepsy and major depressive disorder.
Mr. Tang Yanggang, Executive Director and President of Livzon Pharmaceutical, stated:"This collaboration with NeurAxon Pharmaceuticals will further expand Livzon Pharmaceutical's pipeline in the field of mental and neurological disorders. We are optimistic about the future market potential of NS-041, and both parties will leverage their respective advantages to accelerate the market launch of NS-041."
Dr. Shen Huaqiong, Founder and CEO of NeurAxon Pharmaceuticals, stated:"We are pleased to reach this agreement with Livzon Pharmaceutical regarding NS-041, which recognizes our R&D capabilities at NeurAxon Pharmaceuticals and demonstrates our confidence in Livzon Pharmaceutical's future commercialization capabilities. As an innovative drug with a new mechanism of action, NS-041 is expected to address unmet needs in various central nervous system diseases, possessing global competitiveness and significant commercial potential. The two parties will closely collaborate in the subsequent clinical development to jointly advance the development process of NS-041."
About Livzon Pharmaceutical:Livzon Pharmaceutical Group Inc. (000513.SZ, 01513.HK) was established in 1985, with a registered capital of 926 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production, and sales, with nearly 9,000 employees. Livzon is committed to the R&D, production, and sales of active pharmaceutical ingredients, small molecule drugs, macromolecules, and diagnostic reagents, with key therapeutic areas covering oncology, assisted reproduction, gastrointestinal, anti-infection, and mental/neurological fields.
About NeurAxon Pharmaceuticals:NeurAxon Pharmaceuticals is an international biotechnology company in the clinical stage, focusing on developing innovative therapies for neurological and psychiatric diseases. The company has R&D centers in Shanghai, China, and Boston, USA, and boasts a world-class new drug R&D team in the field of neurological and psychiatric diseases, with senior leaders from academia and industry joining its board of directors and scientific advisory board. The company has established a rich and leading CNS pipeline, with core projects undergoing clinical development and possessing best-in-class potential.
Related Information